Pathological pigmentation of the skin and palate caused by continuous use of chloroquine
Case Report
DOI:
https://doi.org/10.5935/2525-5711.20170030Palabras clave:
Pigmentation, Chloroquine, Antimalarials, Drug ToxicityResumen
Introduction: Chloroquine diphosphate is an antimalarial drug commonly used in the treatment of autoimmune diseases, such as systemic lupus erythematosus and rheumatoid arthritis. Chronic use of this drug may cause toxicity and lead to irreversible visual loss. Objective: To report a case of pathological pigmentation of the skin and oral mucosa caused by the use of chloroquine diphosphate. Case report: A 40-year-old female patient used daily doses of chloroquine (250 mg) to treat rheumatoid arthritis. After using this antimalarial drug for two years, the patient exhibited pathological pigmentations in the hard palate and skin of the lower limbs. To prevent retinal damage, given the toxicity observed in the skin and mucous membranes, the medical team replaced this antimalarial drug. Conclusion: Pathological pigmentation is a sign of drug toxicity and may serve as a warning for health professionals in order to prevent macular diseases caused by an- timalarial agents. We emphasize the importance of dental surgeons for the differential diagnosis of pathological pigmentation of the oral mucosa, as well as the importance of multidisciplinary work involving other health sectors to prevent the onset or worsening of clinical problems in these patients.
Citas
Kauzman A, Pavone M, Blanas N, Bradley G. Pigmented lesions of the oral cavity: review, differential diagnosis, and case presentations. J Can Dent Assoc. 2004;70:682-3.
Rainsford KD, Parke AL, Clifford-Rashotte M, Kean WF. Therapy and pharmacological properties of hydroxychloroquine and chloroquine in treatment of systemic lupus erythematosus, rheumatoid arthritis and related diseases. Inflammopharmacology. 2015;23:231-69.
da Mota LM, Cruz BA, Brenol CV, Pereira IA, Rezende-Fronza LS, Bertolo MB, et al.; Brazilian Society of Rheumatology. 2012 Brazilian Society of Rheumatology Consensus for the treatment of rheumatoid arthritis. Rev Bras Reumatol. 2012;52:152-74.
Gallo CB, Luiz AC, Ferrazzo KL, Migliari DA, Sugaya NN. Drug-induced pigmentation of hard palate and skin due to chronic chloroquine therapy: report of two cases. Clin Exp Dermatol. 2009;34:e266-67.
de Andrade BA, Fonseca FP, Pires FR, Mesquita AT, Falci SG, Dos Santos Silva AR, et al. Hard palate hyperpigmentation secondary to chronic chloroquine therapy: report of five cases. J Cutan Pathol. 2013;40:833-8.
de Melo Filho MR, da Silva CA, da Rocha Dourado M, de Oliveira Pires MB, Pêgo SP, de Freitas EM. Palate hyperpigmentation caused by prolonged use of the anti-malarial chloroquine. Head Neck Pathol. 2012;6:48-50.
Moraes PC, Noce CW, Thomaz LA, Cintra ML, Correa ME. Pigmented lichenoid drug eruption secondary to chloroquine therapy: an unusual presentation in lower lip. Minerva Stomatol. 2011;60:327-32.
Kleinegger CL, Hammond HL, Finkelstein MW. Oral mucosal hyperpigmentation secondary to antimalarial drug therapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2000;90:189-94.
Marmor MF, Kellner U, Lai TY, Melles RB, Mieler WF; American Academy of Ophthalmology. Recommendations on Screening for Chloroquine and Hydroxychloroquine Retinopathy (2016 Revision). Ophthalmology. 2016;123:1386-94.
Chiowchanwisawakit P, Nilganuwong S, Srinonprasert V, Boonprasert R, Chandranipapongse W, Chatsiricharoenkul S, et al. Prevalence and risk factors for chloroquine maculopathy and role of plasma chloroquine and desethylchloroquine concentrations in predicting chloroquine maculopathy. Int J Rheum Dis. 2013;16:47-55.
Lippard VW, Kauer GL Jr. Pigmentation of the palate and subungual tissues associated with suppressive quinacrinehydrochloride therapy. Am J Trop Med Hyg. 1945;25:469-71.
Lerman MA, Karimbux N, Guze KA, Woo SB. Pigmentation of the hard palate. Oral Surg Oral Med Oral Pathol Oral Radiol Endod. 2009;107:8-12.
Melikoglu MA, Melikoglu M, Gurbuz U, Budak BS, Kacar C. Hydroxychloroquine induced hyperpigmentation: a case report. J Clin Pharm Ther. 2008;33:699-701.
Jallouli M, Francès C, Piette JC, Huong du LT, Moguelet P, Factor C, et al.; Plaquenil LUpus Systemic Study Group. Hydroxychloroquine-induced pigmentation in patients with systemic lupus erythematosus: a case-control study. JAMA Dermatol. 2013;149:935-40.
Lacava AC. Ocular complications of chloroquine and derivatives therapy. Arq Bras Oftalmol. 2010;73(4):384-9.
